A hybrid PKPD agent-based model of the tumour immune interaction: effects of anti-cancer combination therapy

We have developed a three dimensional hybrid multiscale agent-based ODE PDE model including tumour immune interaction, cell cycle phases, oxygen and drug diffusion dynamics, the pharmacodynamics of chemotherapy, targeted therapies, immunotherapy, radiotherapy and the respective systemic exposure levels of pharmacological treatments (described by pharmacokinetic modelling). The aim of this model is to support understanding of the spatial-temporal dynamic interactions between cancer cells, the relevant immune cells, and targeted therapies’ molecular moieties, which interact simultaneously in the tumour microenvironment. This interaction is further investigated in the context of combination therapies, thus making some inroads in the mechanistic understanding of positive and negative synergies when multiple therapies are administered. This work addresses the role of temporal sequencing in combination therapies, which requires the simultaneous modelling of multiple system components.

Institutions

Publication Details

Journal
Journal of Pharmacokinetics and Pharmacodynamics
Published
2026-03-24
DOI
https://doi.org/10.1007/s10928-026-10021-2
Primary Topic
Mathematical Biology Tumor Growth
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A hybrid PKPD agent-based model of the tumour immune interaction: effects of anti-cancer combination therapy

Journal of Pharmacokinetics and Pharmacodynamics
Mathematical Biology Tumor Growth
article

A hybrid PKPD agent-based model of the tumour immune interaction: effects of anti-cancer combination therapy

article en

Abstract

We have developed a three dimensional hybrid multiscale agent-based ODE PDE model including tumour immune interaction, cell cycle phases, oxygen and drug diffusion dynamics, the pharmacodynamics of chemotherapy, targeted therapies, immunotherapy, radiotherapy and the respective systemic exposure levels of pharmacological treatments (described by pharmacokinetic modelling). The aim of this model is to support understanding of the spatial-temporal dynamic interactions between cancer cells, the relevant immune cells, and targeted therapies’ molecular moieties, which interact simultaneously in the tumour microenvironment. This interaction is further investigated in the context of combination therapies, thus making some inroads in the mechanistic understanding of positive and negative synergies when multiple therapies are administered. This work addresses the role of temporal sequencing in combination therapies, which requires the simultaneous modelling of multiple system components.

Journal of Pharmacokinetics and PharmacodynamicsVol. 53(3)
AstraZeneca (United Kingdom) (GB), Ablynx (Belgium) (BE), University of Leeds (GB), Age UK (GB), AstraZeneca (South Korea) (KR)
Good health and well-being
Openalex Percentile: Top 13%
Mathematical Biology Tumor Growth
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.